Doctors leading a global war on heart disease say they are "devas...
Doctors leading a global war on heart disease say they are "devastated" by the loss of a new drug they had expected to be an important weapon in the fight against high cholesterol.
Pfizer had hoped to get federal approval next year to sell its
The announcement over the weekend that Pfizer had halted development o...
The announcement over the weekend that Pfizer had halted development of a potential blockbuster drug intended to treat heart disease dealt a major blow not only to the company, but to heart patients everywhere. Researchers had hoped the drug, torcetrapib,
Pfizer Inc. may fall short in convincing federal regulators that its p...
Pfizer Inc. may fall short in convincing federal regulators that its painkiller Celebrex should receive expanded approval to treat children with a devastating form of arthritis, according to documents released Tuesday.
Pfizer wants Food and Drug Admin
Pfizer Inc.'s new experimental heart drug is dead, but the dual approa...
Pfizer Inc.'s new experimental heart drug is dead, but the dual approach the company was testing -- boosting good cholesterol while lowering the bad -- is very much alive, specialists said Monday.
A drug already on the market, Niaspan, raises good chol
Pfizer Inc. may fall short in convincing federal regulators that its p...
Pfizer Inc. may fall short in convincing federal regulators that its painkiller Celebrex should receive expanded approval to treat children with a devastating form of arthritis, according to documents released Tuesday.
Pfizer wants Food and Drug Admini
The discovery that an experimental cholesterol drug is dangerous is a ...
The discovery that an experimental cholesterol drug is dangerous is a major setback for what has been considered one of the most promising new approaches to fighting the nation's leading killer, experts said yesterday.
Pfizer Inc. abruptly announced la
Federal advisers recommended Wednesday that Pfizer Inc. be allowed to ...
Federal advisers recommended Wednesday that Pfizer Inc. be allowed to market the painkiller Celebrex as a treatment for children with a devastating form of arthritis, even though they split on whether it was safe.